Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL versus PROMPT PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL versus PROMPT PHENYTOIN SODIUM.
LAMICTAL vs PROMPT PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
None Documented
None Documented
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant